What Is Retatrutide?
Retatrutide gets attention because of trial data. Australia still has no approved medicine today.
Direct answer
Retatrutide is an investigational GLP-1, GIP, and glucagon receptor agonist being studied by Eli Lilly. It is not an approved Australian medicine as of 24 May 2026. If you are comparing research-grade retatrutide pages, do not buy the headline. Check the strength options, batch ID, COA, HPLC purity, payment protection, dispatch origin, and research-only boundary before payment.
Reviewed for
Investigational status
No medical advice
Research-only buyer boundary
Published 24 May 2026. Medical reviewer pending. No clinician credential is claimed.
The useful split
Direct answer
Trial headlines are not product proof.
A future pharmaceutical product and a current research-grade vial are different buying paths.
The safe comparison is what the seller shows before payment: price, strength, batch, COA, HPLC, PayPal, and dispatch.
Research peptides are not approved by the TGA for human use. Product links are for buyer protection review, not medical advice.
How we reviewed this article
This article was checked against primary source material, regulator pages, and the buyer checklist used across this site. The goal is to keep what is retatrutide? useful without turning it into medical advice or a fake clinical recommendation.
Checked points
Investigational status
No medical advice
Research-only buyer boundary